Cargando…

The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development

Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide synthesized via the activity of the ATP-dependent enzyme carnosine synthetase 1 and can be found at a very high concentration in tissues with a high metabolic rate, including muscles (up to 20 mM) and brain (up to 5 mM). Because of its w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonaccorso, Angela, Privitera, Anna, Grasso, Margherita, Salamone, Sonya, Carbone, Claudia, Pignatello, Rosario, Musumeci, Teresa, Caraci, Filippo, Caruso, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300694/
https://www.ncbi.nlm.nih.gov/pubmed/37375726
http://dx.doi.org/10.3390/ph16060778
_version_ 1785064638620106752
author Bonaccorso, Angela
Privitera, Anna
Grasso, Margherita
Salamone, Sonya
Carbone, Claudia
Pignatello, Rosario
Musumeci, Teresa
Caraci, Filippo
Caruso, Giuseppe
author_facet Bonaccorso, Angela
Privitera, Anna
Grasso, Margherita
Salamone, Sonya
Carbone, Claudia
Pignatello, Rosario
Musumeci, Teresa
Caraci, Filippo
Caruso, Giuseppe
author_sort Bonaccorso, Angela
collection PubMed
description Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide synthesized via the activity of the ATP-dependent enzyme carnosine synthetase 1 and can be found at a very high concentration in tissues with a high metabolic rate, including muscles (up to 20 mM) and brain (up to 5 mM). Because of its well-demonstrated multimodal pharmacodynamic profile, which includes anti-aggregant, antioxidant, and anti-inflammatory activities, as well as its ability to modulate the energy metabolism status in immune cells, this dipeptide has been investigated in numerous experimental models of diseases, including Alzheimer’s disease, and at a clinical level. The main limit for the therapeutic use of carnosine is related to its rapid hydrolysis exerted by carnosinases, especially at the plasma level, reason why the development of new strategies, including the chemical modification of carnosine or its vehiculation into innovative drug delivery systems (DDS), aiming at increasing its bioavailability and/or at facilitating the site-specific transport to different tissues, is of utmost importance. In the present review, after a description of carnosine structure, biological activities, administration routes, and metabolism, we focused on different DDS, including vesicular systems and metallic nanoparticles, as well as on possible chemical derivatization strategies related to carnosine. In particular, a basic description of the DDS employed or the derivatization/conjugation applied to obtain carnosine formulations, followed by the possible mechanism of action, is given. To the best of our knowledge, this is the first review that includes all the new formulations of carnosine (DDS and derivatives), allowing a decrease or complete prevention of the hydrolysis of this dipeptide exerted by carnosinases, the simultaneous blood–brain barrier crossing, the maintenance or enhancement of carnosine biological activity, and the site-specific transport to different tissues, which then offers perspectives for the development of new drugs.
format Online
Article
Text
id pubmed-10300694
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103006942023-06-29 The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development Bonaccorso, Angela Privitera, Anna Grasso, Margherita Salamone, Sonya Carbone, Claudia Pignatello, Rosario Musumeci, Teresa Caraci, Filippo Caruso, Giuseppe Pharmaceuticals (Basel) Review Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide synthesized via the activity of the ATP-dependent enzyme carnosine synthetase 1 and can be found at a very high concentration in tissues with a high metabolic rate, including muscles (up to 20 mM) and brain (up to 5 mM). Because of its well-demonstrated multimodal pharmacodynamic profile, which includes anti-aggregant, antioxidant, and anti-inflammatory activities, as well as its ability to modulate the energy metabolism status in immune cells, this dipeptide has been investigated in numerous experimental models of diseases, including Alzheimer’s disease, and at a clinical level. The main limit for the therapeutic use of carnosine is related to its rapid hydrolysis exerted by carnosinases, especially at the plasma level, reason why the development of new strategies, including the chemical modification of carnosine or its vehiculation into innovative drug delivery systems (DDS), aiming at increasing its bioavailability and/or at facilitating the site-specific transport to different tissues, is of utmost importance. In the present review, after a description of carnosine structure, biological activities, administration routes, and metabolism, we focused on different DDS, including vesicular systems and metallic nanoparticles, as well as on possible chemical derivatization strategies related to carnosine. In particular, a basic description of the DDS employed or the derivatization/conjugation applied to obtain carnosine formulations, followed by the possible mechanism of action, is given. To the best of our knowledge, this is the first review that includes all the new formulations of carnosine (DDS and derivatives), allowing a decrease or complete prevention of the hydrolysis of this dipeptide exerted by carnosinases, the simultaneous blood–brain barrier crossing, the maintenance or enhancement of carnosine biological activity, and the site-specific transport to different tissues, which then offers perspectives for the development of new drugs. MDPI 2023-05-23 /pmc/articles/PMC10300694/ /pubmed/37375726 http://dx.doi.org/10.3390/ph16060778 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bonaccorso, Angela
Privitera, Anna
Grasso, Margherita
Salamone, Sonya
Carbone, Claudia
Pignatello, Rosario
Musumeci, Teresa
Caraci, Filippo
Caruso, Giuseppe
The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development
title The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development
title_full The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development
title_fullStr The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development
title_full_unstemmed The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development
title_short The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development
title_sort therapeutic potential of novel carnosine formulations: perspectives for drug development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300694/
https://www.ncbi.nlm.nih.gov/pubmed/37375726
http://dx.doi.org/10.3390/ph16060778
work_keys_str_mv AT bonaccorsoangela thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT priviteraanna thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT grassomargherita thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT salamonesonya thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT carboneclaudia thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT pignatellorosario thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT musumeciteresa thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT caracifilippo thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT carusogiuseppe thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT bonaccorsoangela therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT priviteraanna therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT grassomargherita therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT salamonesonya therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT carboneclaudia therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT pignatellorosario therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT musumeciteresa therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT caracifilippo therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment
AT carusogiuseppe therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment